Vivek Upadhya is an associate at Grant & Eisenhofer, focusing on securities, appraisal, whistleblower/qui tam and complex pharmaceutical and medical device litigation.
Mr. Upadhya is currently representing clients in a derivative suit against Tesla’s board of directors and has previously represented investors challenging mergers, including an action against Regency Energy Partners pending in the Delaware Court of Chancery. Mr. Upadhya was also involved in In re JPMorgan Chase & Co Securities Litigation (S.D.N.Y.), which resulted in a $150 million settlement. His other recent work includes Delaware Chancery Appraisal cases In re Appraisal of Jarden Corporation and In re Appraisal of Solera Holdings, Inc. Additionally, Mr. Upadhya worked on multi-district litigation involving prescription drugs such as Xarelto and Zofran.
Mr. Upadhya received his J.D. from Emory University School of Law, where he served as a managing editor for the Emory Law Journal. He received his B.A. in law and political science from the University of Utrecht in the Netherlands, and was born and raised in India.